1
|
Goussault R, Frenard C, Varey E, Vrignaud F, Lecerf P, Khammari A, Dréno B. Évaluation de la réponse attendue au traitement par anti-PD1 chez les patients avec un mélanome de stade IIIc-IV à l’aide de l’intelligence artificielle. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Piroth M, Frenard C, Quereux G, Khammari A, Corvec S, Dréno B. Gut dysbiosis: not only with checkpoint inhibitors! Clin Exp Dermatol 2019; 45:247-249. [PMID: 31222907 DOI: 10.1111/ced.14018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/08/2019] [Indexed: 11/29/2022]
Affiliation(s)
- M Piroth
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France
| | - C Frenard
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - G Quereux
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - A Khammari
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - S Corvec
- Bacteriology and Hygiene Department, Hôtel-Dieu, Nantes University Hospital, CRCINA, University of Nantes, Nantes, France
| | - B Dréno
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| |
Collapse
|
3
|
Barthel CC, Frenard C, Aubert H, Chiaverini C, Barbarot S. Épidermolyse bulleuse prétibiale : une dermatose trompeuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
4
|
Frenard C, Dutartre H, Boisrobert A, Khammari A, Dreno B. Decreased photosensitivity to UVA on vemurafenib combined with cobimetinib. J Eur Acad Dermatol Venereol 2018; 33:e87-e88. [PMID: 30198584 DOI: 10.1111/jdv.15239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C Frenard
- Dermatology Department, Nantes University Hospital, CRCINA, Nantes University, Nantes, France
| | - H Dutartre
- Dermatology Department, Nantes University Hospital, CRCINA, Nantes University, Nantes, France
| | - A Boisrobert
- Dermatology Department, Nantes University Hospital, CRCINA, Nantes University, Nantes, France
| | - A Khammari
- Dermatology Department, Nantes University Hospital, CRCINA, Nantes University, Nantes, France
| | - B Dreno
- Dermatology Department, Nantes University Hospital, CRCINA, Nantes University, Nantes, France
| |
Collapse
|
5
|
Frenard C, Dagnelie MA, Khammari A, Saint-Jean M, Boisrobert A, Corvec S, Dreno B. Do Cutibacterium acnes
and Staphylococcus aureus
define two different types of folliculitis? J Eur Acad Dermatol Venereol 2018; 32:e266-e268. [DOI: 10.1111/jdv.14793] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 01/04/2018] [Indexed: 12/22/2022]
Affiliation(s)
- C. Frenard
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| | - M-A. Dagnelie
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| | - A. Khammari
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| | - M. Saint-Jean
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| | - A. Boisrobert
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| | - S. Corvec
- Service de Bactériologie-Hygiène Hospitalière CHU de Nantes; Nantes France
- CRCINA; INSERM; Université d'Angers; Université de Nantes; Nantes France
| | - B. Dreno
- Skin Cancer Unit; Nantes University Hospital; INSERM U1232; Nantes Cedex France
| |
Collapse
|
6
|
Frenard C, Dutartre H, Khammari A, Quereux G, Peuvrel L, Jean MS, Boisrobert A, Dreno B. Photosensibilité aux UVA sous thérapie ciblée combinée par vémurafénib et cobimétinib. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Frenard C, Knol AC, Le Moigne M, Khammari A, Dreno B. Effet de l’indoléamine-2,3-dioxygénase sur les cellules de mélanome. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Frenard C, Planade O, Lot A, Bourreille A, Douane F, Barbarot S. Livedo systématisé : une complication de la chimioembolisation. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Frenard C, Peuvrel L, Saint-Jean M, Brocard A, NGuyen JM, Khammari A, Quereux G, Dreno B. Étude de la survenue de métastases cérébrales sous traitement par ipilimumab de mélanomes métastatiques. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Frenard C, Vincent M, Piram M, Barbarot S. Syndrome encephalocraniocutaneous lipomatosis (ECCL) : une cause rare d’aplasie cutanée multifocale du cuir chevelu. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, Khammari A, Quereux G, Dreno B. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neurooncol 2015; 126:355-60. [PMID: 26511495 DOI: 10.1007/s11060-015-1977-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 10/25/2015] [Indexed: 11/30/2022]
Abstract
UNLABELLED Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases. OBJECTIVES To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases.
Collapse
Affiliation(s)
- C Frenard
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - L Peuvrel
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - M Saint Jean
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A Brocard
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A C Knol
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - J M Nguyen
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A Khammari
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - G Quereux
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - B Dreno
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France.
| |
Collapse
|
12
|
Carapito R, Isidor B, Guerouaz N, Untrau M, Radosavljevic M, Launay E, Cassagnau E, Frenard C, Aubert H, Romefort B, Le Caignec C, Ott L, Paul N, Barbarot S, Bahram S. HomozygousIL36RNmutation andNSD1duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist. Br J Dermatol 2014; 172:302-5. [DOI: 10.1111/bjd.13261] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R. Carapito
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| | - B. Isidor
- Service de Génétique Médicale; Hôpital Mère-Enfant; Nantes France
- INSERM, UMR 957; Nantes France
| | - N. Guerouaz
- Service de Dermatologie; Hôpital Hôtel Dieu; Nantes France
| | - M. Untrau
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| | - M. Radosavljevic
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| | - E. Launay
- Clinique Médicale Pédiatrique; Hôpital Mère-Enfant; Nantes France
| | - E. Cassagnau
- Service d'Anatomie Pathologique; CHU Hôtel Dieu; Nantes France
| | - C. Frenard
- Service de Dermatologie; Hôpital Hôtel Dieu; Nantes France
| | - H. Aubert
- Service de Dermatologie; Hôpital Hôtel Dieu; Nantes France
| | - B. Romefort
- Unité de Cardiologie Pédiatrique; CHU de Nantes; Nantes France
| | - C. Le Caignec
- Service de Génétique Médicale; Hôpital Mère-Enfant; Nantes France
| | - L. Ott
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| | - N. Paul
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| | - S. Barbarot
- Service de Dermatologie; Hôpital Hôtel Dieu; Nantes France
| | - S. Bahram
- Plateforme GENOMAX; Laboratoire d'ImmunoRhumatologie Moléculaire; INSERM UMR_S1109; Centre de Recherche d'Immunologie et d'Hématologie; Faculté de Médecine; Fédération de Médecine Translationnelle de Strasbourg; Université de Strasbourg; 4 Rue Kirschleger 67085 Strasbourg Cedex France
| |
Collapse
|
13
|
Frenard C, Peuvrel L, Brocard A, Saint Jean M, Dreno B, Quereux G. Réponse spectaculaire d’un carcinome de Merkel sous imatinib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|